Mavelertinib

DB16228InvestigationalSmall molecule

Mavelertinib is under investigation in clinical trial NCT02349633 (Study for Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)).

Chemical structure of Mavelertinib
Mechanism
Curator reviewed
Formula / weight
C18H22FN9O2 · 415.433 g/mol (avg)
Also known as
Egfr t790m inhibitor pf-06747775
Code names
PF-06747775

Resolves to

Compound
UNIIYXX2180047CAS1776112-90-3ChEMBLCHEMBL3989970
Structure
InChIKeyJYIUNVOCEFIUIU-GHMZBOCLSA-NSMILESCOC1=NN(C)C=C1NC1=NC(=NC2=C1N=CN2C)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C
Targets
P00533EGFR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Mavelertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In